Abstract: The present study was to find the role of prostaglandin (PG) analogue (Latanoprost) and an effort to develop its anti-glaucoma ophthalmic solution (using solubility agents via safe preservative system). To formulate the eye drops of Latanoprost wherein benzalkonium chloride (BKC; cause external disturbance of the corneal epithelium) was replaced with sodium perborate as the preservative using optimize concentration of surfactant's for better aqueous solubility and evaluated its effectiveness in ocular drug delivery system. The results obtained during the optimization of process in conjunction with process parameters are showed maximum solubility and stability with Tween-80 (Polysorbate-80) in water (0.25% w/v) in phosphate buffer at pH 6.8. In the presence of phosphonic acid, sodium perborate (0.3 mg) has maximum stability at pH ranging from six to seven which gave optimum preservative action during the preservative efficacy test (PET). Due to the results of the assay of the drug and preservative content, and minimizes leaching of impurities Eto sterilized vials were used for storage as compared to gamma sterilized vials. Also, the stability study (short term excursion, freeze thaw and thermal cycling studies), there is no significant change has been observed. The formulation was stable enough with better shelf-life and potency, withstand in extreme temperature condition during shipment.
INTRODUCTION
Glaucoma is characterized by elevated levels of intraocular pressure (IOP) and slowly progressive degeneration of the retinal ganglion cells (RGCs) and the optic nerve axons, leading to increase in the deterioration of the visual field lead to irreversible blindness. The average IOP of the normal human eye is 15.5 ± 21.57mmHg. Intraocular pressure of 20.5mm Hg or more could be an indication of glaucoma, and IOP over 24mmHg is a definite case of glaucoma. A number of categories of drugs have been used to treat Glaucoma such as prostaglandin analogue (PG) inhibitors, α-adrenergic blockers, cholinergic Agonist, α 2 -Agonists, adrenergic agonists, systemic and topical carbonic anhydrase inhibitors. Amongst these, prostaglandin analogues (Latanoprost, Bimatoprost, and Taflauprost etc.) are the first line therapy for the treatment of Glaucoma. Latanoprost (hydrophobic and having low aqueous solubility [1] is the most commonly prescribed drug for treatment of Glaucoma because of longer duration of action; potent and effective ocular hypotensive agent; no significant systemic side effects and lowers intraocular pressure more effectively. Due to Latanoprost low aqueous solubility; formulations containing BKC as a preservative which is also acting as a solubility enhancer [2] . But BKC (0.04 to 0.05%) is reported to cause superficial puncture disturbance of the corneal epithelium. The foremost objective of this *Address correspondence to this author at the PDM College of Pharmacy, Sector: 3A, Sarai Aurangabad, Bahadurgarh-124507, Haryana, India; E-mail: vikasruhilo1@gmail.com study was to solve this problem using sodium perborate as a preservative instead of BKC and formulated an ophthalmic solution containing practically insoluble PG analogue Latanoprost. It is an oxidative preservative which is converted to hydrogen peroxide when combined with water and oxidizes cell wall\the membrane of bacteria, affects membrane-bound enzymes, and disrupts protein synthesis. After being installed in the eye, sodium perborate is catalyzed to water and oxygen by enzymes present in the conjunctival sac; reason for selecting sodium perborate for preservative systems. This replaced affected the solubility of the drug, so to enhance the solubility of drug using different solubilizing agents, i.e. surfactants (Tween-80 and Cremophore) which fulfilled our research one goal (solubilisation of drug using surfactant, development and evaluation of optimization of process parameters which enhance drug and preservative content in the formulation with stability). Thus, the main aim of the research work was to substitute BKC with a safe preservative sodium perborate in the ophthalmic solution of Latanoprost.
MATERIAL
The model drug (Latanoprost) was purchased from Chirogate International Inc., Taiwan. Dibasic sodium hydrogen phosphate (anhydrous), sodium di-hydrogen phosphate monohydrate, sodium chloride and tween-80 (Polysorbate80) were purchased from Merck KGaA, Darmstadt, Germany. Sodium perborate and phosphonic acid and potassium permanganate, sulfuric acid orthophosphoric acid, trimethylamine, sodium hydroxide was purchased from Sigma Aldrich Chem. GmbH, Riedstr and Qualigens Fine Chemicals, Mumbai (India) respectively. All analytical grade materials and Milli Q water (Millipore India Pvt. Ltd., Bangalore, India) were used throughout the study.
METHODS
The overall objective of this study was in the development of stable, bio-available dosage forms and maximizes the chances in formulating an acceptable, safe, efficacious and stable product [3] . Latanoprost, a prostaglandin analogue, which is practically insoluble in water, so its solubility was improved\enhanced by using different concentration of surfactants [Based on literature survey Tween-80 (polysorbate-80) and Polyoxyl 40 hydrogenated castor oil (cremophore) [4] two used surfactants] with different trials and then assay was carried out using HPLC analysis and drug concentration was calculated as per the formula given below:
Optimization
The main purpose of this system to prevent the change in pH due to slow release of hydroxyl ion by the glass and the rapid neutralization of any excess of hydrogen and hydroxyl ions within the buffering capacity of the tears. Therefore buffering agents [Citric acid/sodium citrate, acetic acid/sodium acetate and Sodium di-hydrogen phosphate (NaH 2 PO 4 ) /DI-sodium hydrogen phosphate (Na 2 HPO 4 )] most widely used for enhanced solubility and stability of the drug [5] . The choice of preservative package will depend initially on the optimum pH stability of the active material [6] . Lacrimal fluid isotonic with blood, having an isotonicity value corresponds to that of a sodium chloride (0.9%) solution. Ideally, an ophthalmic solution should have this isotonicity value; but the eye can tolerate isotonicity value as low as that of a 0.6% sodium chloride and as high as that of 2.0% sodium chloride solution without marked discomfort [5] . The osmolality of the formulation should be within the specified limits (i.e. 220-320mOsm/Kg).
A broad number of preservatives have been used in the formulation of eye drops (such as benzalkonium  chloride  (BKC),  benzethonium  chloride  and  cetylpyridiniumchloride,  benzyl  bromide,  edta,  phenylmercury nitrate, phenylmercury acetate, thimerosal, merthiolate and phenylmercuryborate, polymyxin b sulphate, chlorhexidine, stabilized oxychloro complex and sodium perborate) and marketed formulations of latanoprost generally contain BKC as the preservative but it is reported that BKC causes superficial puncture disturbance of the corneal epithelium [7] . The preservative test was used in the development of a preservative system within the pharmaceutical preparation but it is now used as a stability indicating test for a preserved product during its shelf life and increasingly as an infrequent check on the robustness of the formulation. The method was founded upon the basic principle of inoculating a product with a micro-organism and taking samples over a defined period to see whether the preservative system was able to reduce the population to desired level in a given time. The importance of this test is to validate the neutralisation of preservative within the formulation to ensure the test system is capable of recovering the surviving micro-organism [8] .
In this study, the solutions with different concentration of sodium perborate such as 50, 75 and 100% containing named as T1, T2, and T3 were prepared and their PET was done to check the optimum range effective against bacteria ( Table 1) . The basic principle of PET was to inoculate sodium perborate with a microorganism, and then sampling over a defined period of time of 7, 14 and 28 days to examine whether the preservative system was able to The twelve batches ( Table 2 ) were prepared to check whether the phosphonic acid was necessary for the stability of sodium perborate or not. The different sodium perborate pH solutions were prepared with mono and di-basic sodium hydrogen phosphate. Each solution was divided into two parts; one part contained phosphonic acid and other was not. The volume of each solution was makeup upto with water (200ml). Then these solutions were charged to stress condition 50°C for 28 days. To check the sodium perborate content after 14 days and then charged again. After 14 days, samples were again taken out and again analysis was done (Ti-trimetry method).
Formulation
Firstly, buffer solution was ready by adding anhydrous disodium hydrogen phosphate (4.70mg/ml) under continuous stirring (until the clear solution was formed), and then sodium di-hydrogen phosphate monohydrate (4.60mg/ml)) was added similarly followed by sodium chloride (4.10mg/ml) into the milli-Q water (equivalent to 80% of the batch size). In another beaker, Tween-80 (2.00mg/ml) was taken and solubilises it with water, then added the accurate quantity of model drug (0.05mg/ml), sonicated the solution (Sonicator, Effem Technologies, New Delhi, India) until it solubilised completely. The resulting solution transferred into the buffer solution with addition of phosphonic acid (0.05mg/ml) then sodium perborate (0.30mg/ml) to it and make up the volume with milli-Q water (up to the batch size). All the formulations were checked for general appearance i.e. color, clarity and any suspended particulate matter, etc. The clarity was checked by using a wooden board with black and white background. The vials were held horizontally and gently rotated immediately under the lamp and then inverted once or twice to detect foreign particles [12] . After preparation as well as after one to two hours of storage at room temperature [13] , ophthalmic solution pH was recorded immediately using pH meter [it was calibrated before each use with buffer solutions at pH 4, 7 and 10 (pH Meter and Conductivity Meter, Orion, India)].
The drug content analysis was used using High Performance Liquid Chromatography (HPLC, Waters 2996, and Waters, India) by prepared the standard solution of drug (API 25mg) with methanol (2ml) and make up the volume (50ml) then take five milli litres of above solution and make up the volume (100ml). The sample solution (5ml) diluted with diluent (10ml) and the assay was done by injected sample (20µl) into the HPLC system [Cosmosil Column {C-18, 5µm (250mm x 4.6mm)}, column oven temperature, 40°C using flow rate: 1.8ml/min and run time: 50min with mobile phase [buffer {Orthophosphoric acid (5.8ml) plus Triethylamine (1ml) make up the volume (1000ml), adjust pH 5 with NaOH}: ACN (50:50)] at λ max of 210 nm. The standard curve was prepared to check the sensitivity and linearity of the method.
The sample solution of sodium perborate (0.30g) was dissolved in water (50ml) and then ten millilitre of this solution was taken and diluted again with water (50 ml). The resulting solution (50ml) was taken in a conical flask, dilute with sulphuric acid was (10ml) and it was titrated with potassium permanganate solution (0.005M). 
Evaluation
The accurate weighed the five times one, two, five and ten drops of formulation and calculated average weight of drop size and osmolality measured by using Osmometer (Model 3250 Advanced instruments Inc., India).
Hold Time Study
The purpose of this study is to optimize the effect of formulation while it is on hold in holding tank in the plant. Furthermore to know the compatibility of formulation with stainless steel container (Grade 316L) by keeping the formulation (250ml) in the container at 2-8°C, then the sample was withdrawn in 04, 07 and 24 hrs from then analyzed it (pH, assay of drug and preservative content).
Preservative Efficacy Test (PET)
The antimicrobial effectiveness test was designed and to evaluate how well a product\formulation withstands microbial contamination while being used [14] . The method was similar in both British Pharmacopeia (BP) and United States Pharmacopeia (USP) but sampling times and logarithmic (log) reduction performance criteria of the BP are more stringent than those in the USP [10, 11] .
Container Selection Study
This technique is used by the Centre for Food Safety and Applied Nutrition (CFSAN) to evaluate the safety of substances that are proposed as indirect food additives [15] . These drug products are usually solutions marketed in a leaking defects packaging evaluation bottle with a dropper built into the neck. A few solution products use a glass container due to stability concerns regarding plastic packaging components.
The American Academy of Ophthalmology (AAO, Table 3 ) recommended a uniform color coding system be established for the caps and labels of all topical ocular medications [16] . In our study the ophthalmic solution was filled in Eto Sterilized and Gamma sterilized vials and then analyzed.
Stability Studies [17, 18]
The accelerated permanence should include testing of those attributes of the drug product that are susceptible to change during storage and are likely to influence quality, safety, and/or efficacy. The testing should cover, as appropriate, the physical, chemical, biological, and microbiological attributes, preservative content (e.g., antioxidant, antimicrobial preservative), and functionality tests (e.g., for a dose delivery system). The longer and accelerated stability analysis was conducted to store for the formulation in Etosterilized containers for a period of days in a humidity chamber (Table 4 and 5). 
Thermal Excursion Study
Pharmaceutical products should be shipped in a manner that ensures products will not be adversely affected by environmental conditions on the basis of product stability, product history, packaging information and the transport system used. Study, will evaluate the chemical (e.g. Potency, related substances) and physical (particulates and physical appearance, including primary packing's) properties of the drug products. Test results must meet appropriate specification by using validated stability indicating methods. 
Short Term Excursion Study
It was to be designed by anticipating the extreme high and low temperature conditions that may occur during drug product shipment on the basis of the drug products known properties. In our study, the samples are prepared by filling the formulation in Eto sterilized vial, nozzle was applied and capped with HDPE turquoise cap, R and D labels were applied and then packed in unit carton with ifu) were kept in deep freezer (Blue Star, India) for two days and then at 40°C and 75% RH for next two days and testing parameters such as pH, osmolality, assay of drug and preservative content.
Freeze Thaw Study
It's likely that the product will be shipped via trucks or rail cars. These vehicles are rarely equipped with temperature controls so it is likely that your product may freeze one day and be in hot temperatures another. It is crucial that the formula is able to withstand extreme, rapid temperature changes. To do a thorough freeze-thaw test the standard method for testing of samples is; prepared samples (three test, control), took initial readings and freeze test samples for 24 hours. After that remove the samples and allow thawing at room temperature for 24 hours and then sending the sample for analysis.
Thermal Cycling Study
This study was to be designed by anticipating with fluctuating environmental conditions which may occur during drug product distribution. This study was run on the final formulation in the marketed package. If the formulation or primary package changes, these studies should be repeated, unless otherwise scientifically justified. The samples were kept in the deep freezer and then exposed at accelerated conditions for two days as a one cycle and same process was continued for three cycles, samples of final cycle were submitted for analysis.
RESULTS AND DISCUSSION
For development of stable and bio-available dosage forms; to achieve maximum solubility of Latanoprost in water determined with surfactant by using HPLC (HPLC 2960, Water, India). From the solubility enhancement data ( Table 6 ) maximum aqueous solubility was observed in Trail 5 which has 0.25% w/v concentration of Tween-80 in water.
Data Analyses

Buffer Systems and Osmolaity
In Ophthalmic, to avoid the change in pH of the formulation, phosphate buffer system varying with concentration of sodium di-hydrogen phosphate (Table 7) . Additionally, osmolality was maintained by using sodium chloride and different trials [sample (20µl)] were done to adjust the osmolality and calculated the osmolality (Osmometer Model 3250, Advanced instruments Inc., India). Different concentrations of sodium chloride were tried ( Table 8 ) (achieve an osmolality of 267 mOsm/kg, which is close to that of marketed formulation of Latanoprost eye drop) and sodium chloride (NaCl; 0.41%w/v) gives an osmolality of 267mOsm/kg (optimized and selected for formulation of Latanoprost eye drop). 
Preservative and its Stability
All the three trials were evaluated for drug content using HPLC analysis ( Table 9) . From results was concluded that the presence of sodium perborate does not affect the concentration of Latanoprost. Unlike trials T1 and T2, the microbial count of C. albicans and A. niger in trial T3 was found to be nil on the seventh day. Hence, it is compatible with the drug solution, therefore, it was concluded that trial T3 with 100% w/v of sodium perborate (0.30 mg/ml) provides the optimum preservative action and thus, was selected for the formulation of Latanoprost eye drop (Table 10) . To avoid the problem of instability, a number of trials were conducted using sodium perborate in the presence or absence of Phosphonic acid at different pH (Table 11) . Hence, it could be concluded that the most stable pH range of sodium perborate preservative system is between six to seven and which was selected for the formulation of Latanoprost eye drop. 
Characterization
The solution was found to be clear, colorless and transparent solution and pH of a solution was found to be 6.8±0.02 which lies within specified limits, hence the optimum pH for the eye is between 6 to 7.5 i.e. isosmotic. The stock solution of model drug (25.0mg) was prepared by dissolving in methanol (2ml) and then the volume was made up to with mili Q water (100ml). Further dilutions were prepared using a stock solution from concentration 18.2µg/ml to 33.9µg/ml. The prepared dilutions were analyzed for mean area corresponding to each concentration of Latanoprost (Figure 1) . It was observed almost to be a straight line indicating the linearity of the method of analysis. The slope and intercept were found to be 13095 and 477.0 respectively, with regression R 2 =0.999. The assay of Latanoprost was found to be 98.7 ± 0.04, which is within specified limits i.e. 90% to 110%. The principle of titrimetric analysis is defined as the definite volume of the analyte i.e.; the substance to be determined (sodium perborate) is allowed to react with a suitable reagent (potassium permanganate) whose standard solution can be prepared and the volume of the solution consumed for complete reaction is used to find out the concentration of analyte solution. The sample solution was titrated with M Potassium Permanganate (0.005M) (each one millilitre was equivalent to 0.0384 mg of sodium perborate, ( Table 12) . Its content determination was found to be 99.08 ± 0.09% which lays within specified limits i.e. 75% to 125%. Higher concentration of preservative can cause irritation to the eye, whereas lower concentration leads to the failure of preservative action. The osmolality of the formulation was found to be 267 ± 1.5mOsm/kg which is within the specified limits i.e. 220 to 320mOsm/kg (Hyper-osmotic solution leads to shrinkage of eye whereas hyposmotic leads to bulging of the eye therefore, isosmotic solutions should be used). The drop size of the formulation was found to be 31.7µg ± 1.8 within specified limits i.e. 25µg to 50µg (larger is the drop size; greater will be the problem of spillage, leading to the wastage of drug).
Hold Time Study
It is also known as compatibility study and main purpose of this study is to check the stainless steel compatibility with formulation at different temperature while it is kept on hold in holding tank and on the basis of total sum of unknown impurities (Table 13) the container was selected which is suitable for the preparation of formulation.
Container Selection Study
The formulation was stored in respective containers (Eto and Gamma sterilizes vials). Later, samples were withdrawn from each type of vials and evaluated for different parameters. The observations for different test parameters of the formulation packed in Eto sterilized vials. It was observed that the sum of impurities present in samples increased with time i.e. from 0 to 0.16% in 14 days, with only slight change in pH and drug content. It was observed that the sum of total impurities present in samples increased very rapidly with time i.e. 0.29 to 1.74%, whereas assay showed the purity of Latanoprost decreased more rapidly than that of sodium perborate. 
Preservative Efficacy Test (PET)
In this study, formulation of Latanoprost, concentration of sodium perborate (0.3 mg/ml) was used eye drop in order to prevent microbial growth (Table 14) .
Stability Analysis
The optimized formulation of Latanoprost was kept at specified temperature i.e. 25°C and humidity for three months as per ICH guidelines for accelerated stability study. Eye Drop solution was packed in Eto vials and kept in stability chamber maintained at temperature 25°C and humidity 60% RH. Samples were withdrawn at different time intervals i.e. 0, 1, 2, and 3 month, examined its physical evaluation (Table 15 ).
Thermal and Short Term Excursion Study
Pharmaceutical products should be shipped in a manner that ensures products will not be adversely affected by environmental conditions on the basis of product stability, product history, packaging information and the transport system used. Twenty five samples were kept at -20°C to -10°C in deep freezer, then 75% RH at 40°C for next two days. On resulting (Table 16) , there was no significant change in values of testing parameters after and before the short term excursion study.
Freeze Thaw and Thermal Cycling
It will show whether the formula will remain stable under varied conditions that it might experience during the shipping and storage phases of the product life cycle. The final formulation in the marketed package, the samples were deep freezed and then exposed at accelerated condition 40 ± 2°C, 75% RH for two days as a one cycle and same process was continued for three cycles, samples parameters were analysis (Table 16 ).
CONCULISON
Ophthalmic solution of practically insoluble Latanoprost was successfully formulated and sodium perborate showed excellent results for inhibition of growth of both bacteria and fungi. An ideal ophthalmic preparation should be formulated at a pH near the tear fluid pH value in which optimum stability is also achieved. For maximum stability and isotonicity, pH of Latanoprost eye drop was adjusted to 6.8. Hold time study showed compatibility of formulation with stainless steel and passed the test for preservative efficacy (no significant changes) after subjecting it to accelerated stability testing for period of three months; short term extrusion, freeze thaw and thermal cycling studies have shown stability of formulation containing sodium perborate in final dispensing container showed better efficacy, stability, shelf life, and potency compare to BKC to withstand extreme temperature condition during shipment. Thus, it can be concluded that the sodium perborate is better preservative than BKC in Latanoprost eye drops/solution. 
